
CatalYm Moves Visugromab into Phase 2/3 Trials for Cancer Cachexia, Doses First Patient
CatalYm Initiates Phase 2/3 Trial of Visugromab in Cancer Cachexia with First Patient Dosed CatalYm has announced an important milestone in its clinical development pipeline with the dosing of the…













